Zwaan, C. van der

patient platelet study group xemilofiban event /iiia placebo infarction placebo group trial receptor lefradafiban treatment glycoprotein percent 20 mg study drug point inhibition revascularization aggregation investigator level death end point value 48 hours end points artery disease fradafiban platelet aggregation <0.001 angina disease concentration complication table safety 182 days antagonist plasma result angioplasty comparison event rate administration percutaneou erasmus university artery stent downloaded incidence circulation 30 days blockade thrombotic 60 mg 10 mg fibrinogen receptor occupancy blood 24 hours heparin 30 mg heart 45 mg article stenting t r e plasma concentrations vivo platelet aggregation www.heartjnl.com downloaded xemilofiban groups nonfatal syndrome fibrinogen increase university relation month